AIMS: The strength of sedation due to antihistamines can be evaluated by using positron emission tomography (PET). The purpose of the present study is to measure histamineH(1) receptor (H(1)R) occupancy due to olopatadine, a new second-generation antihistamine and to compare it with that of ketotifen. METHODS:Eight healthy males (mean age 23.5 years-old) were studied following single oral administration of olopatadine 5 mg or ketotifen 1 mg using PET with (11)C-doxepin in a placebo-controlled crossover study design. Binding potential ratio and H(1)R occupancy were calculated and were compared between olopatadine and ketotifen in the medial prefrontal (MPFC), dorsolateral prefrontal (DLPFC), anterior cingulate (ACC), insular (IC), temporal (TC), parietal (PC), occipital cortices (OC). Plasma drug concentration was measured, and correlation of AUC to H(1)R occupancy was examined. RESULTS:H(1)R occupancy after olopatadine treatment was significantly lower than that after ketotifen treatment in the all cortical regions (P < 0.001). Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6. Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively. H(1)R occupancy of both drugs correlated well with their respective drug plasma concentrations (P < 0.001). CONCLUSION: It is suggested that 5 mg oral olopatadine, with its low H(1)R occupancy and thus minimal sedation, could safely be used an antiallergic treatment for various allergic disorders. Abbreviations histamineH(1) receptor (H(1)R), histamine H(1) receptor occupancy (H(1)RO), dopamine D(2) receptor (D(2)R), positron emission tomography (PET), blood-brain barrier (BBB), binding potential ratio (BPR), distribution volume (DV).
RCT Entities:
AIMS: The strength of sedation due to antihistamines can be evaluated by using positron emission tomography (PET). The purpose of the present study is to measure histamine H(1) receptor (H(1)R) occupancy due to olopatadine, a new second-generation antihistamine and to compare it with that of ketotifen. METHODS: Eight healthy males (mean age 23.5 years-old) were studied following single oral administration of olopatadine 5 mg or ketotifen 1 mg using PET with (11)C-doxepin in a placebo-controlled crossover study design. Binding potential ratio and H(1)R occupancy were calculated and were compared between olopatadine and ketotifen in the medial prefrontal (MPFC), dorsolateral prefrontal (DLPFC), anterior cingulate (ACC), insular (IC), temporal (TC), parietal (PC), occipital cortices (OC). Plasma drug concentration was measured, and correlation of AUC to H(1)R occupancy was examined. RESULTS: H(1)R occupancy after olopatadine treatment was significantly lower than that after ketotifen treatment in the all cortical regions (P < 0.001). Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6. Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively. H(1)R occupancy of both drugs correlated well with their respective drug plasma concentrations (P < 0.001). CONCLUSION: It is suggested that 5 mg oral olopatadine, with its low H(1)R occupancy and thus minimal sedation, could safely be used an antiallergic treatment for various allergic disorders. Abbreviations histamine H(1) receptor (H(1)R), histamine H(1) receptor occupancy (H(1)RO), dopamine D(2) receptor (D(2)R), positron emission tomography (PET), blood-brain barrier (BBB), binding potential ratio (BPR), distribution volume (DV).
Authors: E A Rabiner; Z Bhagwagar; R N Gunn; P A Sargent; C J Bench; P J Cowen; P M Grasby Journal: Am J Psychiatry Date: 2001-12 Impact factor: 18.112
Authors: M Tagawa; M Kano; N Okamura; M Higuchi; M Matsuda; Y Mizuki; H Arai; R Iwata; T Fujii; S Komemushi; T Ido; M Itoh; H Sasaki; T Watanabe; K Yanai Journal: Br J Clin Pharmacol Date: 2001-11 Impact factor: 4.335
Authors: M Bernardo; E Parellada; F Lomeña; A M Catafau; M Font; J C Gómez; C López-Carrero; F Gutiérrez; J Pavía; M Salamero Journal: Psychiatry Res Date: 2001-08-25 Impact factor: 3.222
Authors: Eugenii A Rabiner; Martin R Wilkins; Federico Turkheimer; Roger N Gunn; Joanna Udo de Haes; Michiel de Vries; Paul M Grasby Journal: J Pharmacol Exp Ther Date: 2002-06 Impact factor: 4.030
Authors: Oana I Stanisor; Sophie A van Diest; Zhumei Yu; Olaf Welting; Noor Bekkali; Jing Shi; Wouter J de Jonge; Guy E Boeckxstaens; Rene M van den Wijngaard Journal: PLoS One Date: 2013-06-12 Impact factor: 3.240
Authors: Magí Farré; Clara Pérez-Mañá; Esther Papaseit; Esther Menoyo; Marta Pérez; Soraya Martin; Santiago Bullich; Santiago Rojas; José-Raúl Herance; Carlos Trampal; Luis Labeaga; Román Valiente Journal: Br J Clin Pharmacol Date: 2014-11 Impact factor: 4.335